Mind Medicine stock dips on proposed securities offering

Mind Medicine ( NASDAQ: MNMD ) shares fell over 5% Friday morning after the biopharmaceutical company proposed a public offering of common shares and pre-funded warrants to purchase common shares. Net proceeds from this offering will be used to fund the research and development of its product candidates and working capital and general corporate purposes. Leerink Partners and Evercore ISI are acting as the joint bookrunning managers for the offering.

RBC Capital Markets and Oppenheimer & Co. are acting as lead managers. More on Mind Medicine MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors Psychedelics Closer To Commercialization; Compass Far And Away The Leader RBC recommends buying MindMed amid psychedelic stocks sell-off (update) Biggest stock movers today: WKME, CRWD, HPE, and more.